NEED A HELP? CALL US

HELPLINE: 626-244-5300

Diagnostics

1. Refractive index Multifractality: Our patent pending technology is based on the fact that spatial variation of refractive index in biological tissues exhibits multifractality and cancer progression is exhibited by distinct changes in multifractal parameters showing considerable promise for highly sensitive pre-cancer detection. NanoScope Technologies has developed novel, non-invasive patent pending Cancer Diagnostic Device as a low powered, safe bright light device that can detect and differentiate cancer tissue from normal tissue and benign tumor. Our technology led to development of new non-invasive, affordable, point-of-care early cancer diagnosis method so that quantitative analysis can be performed in a statistically rigorous manner in near real-time using validated clinical data library and algorithms. Our devices allow reliable, pain-less collection of data can be performed, allowing health caregivers examine all suspicious sites. NanoScope Technologies is beginning clinical trial of this diagnostics technology. Further, we are developing smart-phone mountable NanoSpectro platform for disease diagnosis and food-quality control.

2. Tomographic quantitative microscopy: NanoScope Technologies is developing microscopic/interferometric imaging and analysis tools for visualization of cells and disease diagnosis. This is also used for characterization of biomaterials including intra-ocular lenses.

Therapeutics

1. Vision restoration: Severe loss of vision occurs due to age-related macular degeneration and approximately 11 million people in the US have some form of retinal photodegeneration which is expected to double by 2050. Most of the current clinical treatments are primarily focused on slowing down the progression of the disease, as there is neither a cure that can stop the degeneration nor a therapy, other than retinal prostheses, that can restore vision lost due to the degeneration. NanoScope Technologies has developed multi-characteristics opsins with significantly higher photosensitivity to ambient light, packaged into safe viral vectors that can be delivered to eye via intravitreal injection so as to photosensitize retinal cells in photodegenerated retina. Based on the Small Business Innovation Research Grant from the National Eye Institute of NIH, NanoScope Technologies is conducting preclinical evaluation of this approach for dry-AMD therapy, and also beginning clinical trial of this therapeutic methodology in Asia.

2. Nano-optical delivery: NanoScope Technologies has developed technology based on nano-enhanced optical field of gold nanoparticles which allowed the use of a continuous wave laser beam for efficient delivery of exogenous impermeable materials into targeted cells. Using this Nano-enhanced Optical Delivery method, we have shown that large molecules could be delivered with low power cw laser with exposure time ~ 1sec. At such low power and exposure, the non-targeted cells are not adversely affected by the laser beam. Further, by varying the size of the gold nanoparticles, different targeted cells could be exclusively sensitized to selective wavelengths of laser beam. NanoScope researchers are working to translate this platform technology for delivering various genes and therapeutic molecules into targeted cells in-vivo.

3. Cancer Therapeutics: NanoScope Technologies is developing molecules that can be genetically-targeted to cancer cells, which upon external remote activation lead to targeted destruction of cancer cells.

Instrumentation

1. Cellular manipulator: NanoScope Technologies has developed compact laser micromanipulators for precise manipulation and characterization of cells in suspension as well as those adhered to substrate. Further, instrumentation using non-electromagnetic wave are being developed to manipulate/characterize cells/tissue properties.

2. Neural stimulator: NanoScope is developing multimodal neural stimulation tools for basic studies as well as therapy of various neurodisorders including chronic pain.

3. Cell culture and molecular analysis Platform: At NanoScope, we are developing microfluidic platform for allowing co-cultures of cells under physiologically-controlled environment, which also allows convenient molecular analysis.

Research and Education

While NanoScope Technologies is committed to in-house innovation and technology development, it aims to impact global health and education via partnerships with academic and industrial organizations as well as with government and non-government agencies.  It has long-term goal of supporting/establishing research and education centers for enabling technologies for critical healthcare challenges.

 

It has long-term goal of supporting/establishing research and education centers to advance enabling technologies for critical healthcare challenges.

6500 Greenville Ave, Ste 740, Dallas TX 75206  |  Phone: 626-244-5300  |  Fax: 817-719-2692  | Mail: info@nanoscopetech.com

Copyright @ 2015 Nanoscope  |  All rights reserved